Press release
Global Semaglutides Market Projected to Surpass $41.4 Billion by 2029 with 12.33% Annual Growth
Semaglutides
The rising prevalence of diabetes is expected to propel the semaglutide market. Diabetes, a chronic condition that results in high blood glucose levels, is on the rise due to factors like increasing obesity rates and poor lifestyle choices. Semaglutide aids in managing diabetes by mimicking a natural hormone, improving insulin secretion, reducing glucagon, and slowing gastric emptying, thus helping to lower blood glucose and support weight loss. In 2023, Diabetes Canada reported that approximately 2.4 million Canadians had diabetes, with numbers expected to reach 3 million by 2033, contributing to the market's growth.
Get Your Semaglutides Market Report Here:
https://www.thebusinessresearchcompany.com/report/semaglutides-global-market-report
What Is the projected market size and growth rate for the semaglutides market?
The semaglutides market has expanded rapidly in recent years. It will grow from $23.07 billion in 2024 to $26 billion in 2025, with a CAGR of 12.7%. Growth factors include lifestyle changes leading to higher diabetes rates, increased research and development investment, rising healthcare spending, the expansion of pharmaceutical companies in emerging markets, and growing acceptance of injectable treatments.
The semaglutides market is expected to grow to $41.4 billion by 2029 at a CAGR of 12.3%. Growth drivers include the increasing prevalence of diabetes, the rising demand for effective therapies, government support for diabetes treatment, and the aging population. Trends include digital health integration, AI and machine learning use, telemedicine adoption, wearable technology, 3D printing, and blockchain for supply chain management.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18720&type=smp
What new trends are reshaping the semaglutides market and its opportunities?
Companies in the semaglutides market are enhancing diabetes and obesity treatments through products like GLP-1 receptor analogues, which aim to improve patient adherence and reduce side effects. For instance, in January 2022, Novo Nordisk India launched oral semaglutide, a breakthrough diabetes treatment that was previously only available as an injection. This oral formulation combines semaglutide with SNAC, a substance that enhances absorption and protects it from stomach degradation.
What major market segments define the scope and growth of the semaglutides market?
The semaglutides market covered in this report is segmented -
1) By Brands: Ozempic, Wegovy, Rybelsus
2) By Route Of Administration: Oral, Injection
3) By Application: Type 2 Diabetes, Obesity Management
4) By End-User: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Ozempic: Pen Injection (Auto-Injector), Prefilled Pens (Dosages 0.25mg, 0.5mg, 1mg, 2mg)
2) By Wegovy: Subcutaneous Injection (Auto-Injector), Prefilled Pens (Dosages 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg)
3) By Rybelsus: Oral Tablets (Dosages Of 3mg, 7mg, 14mg)
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18720
Which regions are key players in the growth of the semaglutides market?
North America was the largest region in the semaglutides market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the semaglutides market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which key market leaders are driving the semaglutides industry growth?
Major companies operating in the semaglutides market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=18720&type=smp
What Is Covered In The Semaglutides Global Market Report?
•Market Size Forecast: Examine the semaglutides market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the semaglutides market for a structured understanding.
•Key Players Overview: Analyze major players in the semaglutides market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the semaglutides market.
•Segment Contributions: Evaluate how different segments drive overall growth in the semaglutides market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the semaglutides market.
•Industry Challenges: Identify potential risks and obstacles affecting the semaglutides market.
•Competitive Landscape: Review strategic developments in the semaglutides market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Semaglutides Market Projected to Surpass $41.4 Billion by 2029 with 12.33% Annual Growth here
News-ID: 3934926 • Views: …
More Releases from The Business Research Company
Unlocking Opportunities in the Tyrosine Kinase Inhibitors Market: 2025-2034 Fore …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Tyrosine Kinase Inhibitors Industry Market Size Be by 2025?
The market for tyrosine kinase inhibitors has seen robust growth in recent times. The market is predicted to expand from $58.03 billion in 2024 to $62.66 billion in 2025, marking a compound annual growth rate (CAGR) of…
Sustained Release Excipients Market Advances With Product Innovation Industry Tr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Sustained Release Excipients Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the market size of sustained release excipients has seen significant growth. It's projected to increase from $1.4 billion in 2024 to $1.51 billion in 2025, exhibiting a Compound Annual Growth Rate…
Surge In Cancer Cases Fuels Expansion Of The RNA-Targeting Small Molecule Therap …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the RNA Targeting Small Molecules Therapeutics Market Size By 2025?
In recent years, the market size of RNA targeting small molecules therapeutics has witnessed substantial growth. The market, which is estimated to be worth $6.1 billion in 2024, is projected to increase to $7.83 billion in…
Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025?
In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic…
More Releases for Semaglutide
Rising Diabetes Prevalence Drives Growth in Liraglutide and Semaglutide Markets …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Liraglutide And Semaglutide Industry Market Size Be by 2025?
In recent times, the liraglutide and semaglutide market has seen quick and impressive growth. The growth is projected to continue, with the market size increasing from $15.19 billion in 2024 to an estimated $16.98 billion in 2025,…
Higher max dose guidance for semaglutide offers hope
A new study increases max-dose guidance for semaglutide. This offers hope for those who didn't reach their weight goals. The Injection and Infusion Clinic of ABQ now provides higher-dose weight loss injections, backed by the STEP UP trial, which showed 20.7% average weight loss with higher-dose semaglutide. 33.2% of participants lost over 25% of their body weight. Ideal for those who plateaued, this science-backed treatment supports long-term weight management with…
Recent Developments in the Global Semaglutide Market
Global semaglutide market is anticipated to grow at a significant CAGR of 9.1% during the forecast period (2024-2031). The market growth is driven by the rise in the incidences of diabetes and obesity globally, as it supports controlling blood sugar levels and improving insulin sensitivity. The prolific rise in demand for novel therapies and innovative treatment options, owing to the increasing prevalence of TZDs is also contributing to the market…
Find Trusted Compounding Pharmacies Offering Semaglutide Near You
Compounded semaglutide has gained popularity as an effective treatment for weight loss and diabetes management. If you're looking for a personalized medication solution, finding a trusted compounding pharmacy near you is essential. These specialized pharmacies create customized versions of medications like semaglutide, tailored to your specific health needs.
To find a reliable compounding pharmacy, start by researching local pharmacies with certified pharmacists who specialize in compounding. Check reviews, ensure the pharmacy…
Huateng Pharma Proudly Unveils Its New Product - Semaglutide Side Chains
Huateng Pharma, a distinguished provider of premium pharmaceutical intermediates, proudly unveils its latest breakthrough: Semaglutide Side Chain. This groundbreaking addition to Huateng Pharma's esteemed portfolio signifies a remarkable leap forward in pharmaceutical innovation, showcasing a diverse array of compounds including AEEA-AEEA (CAS NO.: 1143516-05-5), SNAC (CAS NO.: 203787-91-1), tBuO-Ste-Glu(AEEA-AEEA)-OtBu (CAS NO.:1118767-16-0), and Fmoc-L-Lys[Oct-(otBu)-Glu-(otBu)-AEEA-AEEA]-OH (CAS NO.: 1662688-20-1).
Semaglutide Side Chain serves as a pivotal component in the synthesis of semaglutide, an innovative…
Huateng Pharma Develops Intermediates of Semaglutide For TD2
According to the latest IDF Diabetes map, the global prevalence of diabetes reached 10.5% in 2021, with 537 million adults living with diabetes. China has become a disaster zone for diabetes, with the largest number of adults with diabetes in the world. In the past 10 years (2011-2021), the number of people with diabetes in China increased from 90 million to 140 million, an increase of 56%. The total number…
